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Efficacy of Intravitreal Triamcinolone Acetonide for Eyes 
with Postvitrectomy Diabetic Vitreous Hemorrhage
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Department of Ophthalmology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea
Purpose: To evaluate the efficacy of intravitreal triamcinolone acetonide (IVT) for the management of 
postvitrectomy diabetic vitreous hemorrhage.
Methods: The authors conducted a retrospective study of patients with postvitrectomy diabetic vitreous 
hemorrhage who were administered 4 mg (0.1 cc) of triamcinolone acetonide ophthalmic suspension. Ocular 
history, adverse events, BCVA, intraocular pressure, external eye examination, slit-lamp biomicroscopy, 
fundus examination, B-scan ultrasonography, and fundus photography were assessed on day 1, weeks 1, 
2, and 4 and months 2 and 3.
Results: There were 19 eyes of 18 consecutive patients with mean follow-up after IVT injection of 28 
weeks. Of the 19 eyes, 17 eyes (89%) experienced clearing of vitreous hemorrhage within 1 to 5 weeks 
(mean, 1.7 weeks) with visible triamcinolone precipitates along with blood clot in the inferior aspect of 
fundus. Of these 17 eyes, 12 eyes (63%) maintained vitreous hemorrhage-free condition at last follow-up 
with a mean visual acuity of 20/63 (range, 20/320 20/25), whereas 5 (29%) developed recurrent vitreous 
hemorrhage after clearing of vitreous hemorrhage. Vitreous hemorrhage was not cleared in 2 eyes, which 
required surgical procedures.
Conclusions: IVT injection may be beneficial for clearing recurrent postvitrectomy Diabetic Vitreous Hemorrhage.
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The incidence of recurrent vitreous hemorrhage of 
proliferative diabetic retinopathy following posterior vitrectomy 
ranges from 12 % to 63 %.
1-3 Recurrent vitreous hemorrhage 
may be caused by the dissolution of blood clots trapped in 
the remaining anteroperipheral vitreous gel, remnants of 
fibrovascular tissue, reactivation of retinal sites that bled 
intraoperatively, anterior hyaloidal fibrovascular proliferation, 
or neovascularization originating from the sclerotomy sites.
4-5 
This condition is usually managed by fluid-gas exchange or 
vitreous cavity washout.
6-7
Intravitreal triamcinolone acetonide (IVT) has been shown 
to be a useful adjunct therapy for intraocular edematous and 
neovascular disease.
8-12 Corticosteroids are used in the 
treatment of various retinal diseases primarily for their 
anti-inflammatory and anti-angiogenic effects. Corticosteroids 
inhibit prostaglandins and inflammatory adhesion molecules, 
thus contribute to the stabilization of the blood-retinal 
barrier.
13-15 Corticosteroids also inhibit expression of the 
vascular endothelial growth factor (VEGF), as well as the 
induction of VEGF by platelet-derived growth factor (PEGF) 
and platelet activating factor (PAF).
16
We have found that IVT, when used along with vitrectomy 
for the treatment of proliferative diabetic retinopathy, 
facilitates the absorption of macular edema. Follow up 
examinations have shown the triamcinolone precipitates 
downward of vitreous cavity along with retained blood. We 
have therefore assessed the efficacy of IVT for the 
management of postvitrectomy diabetic vitreous hemorrhage.
Materials and Methods
Among the patients at Asan Medical Center from April 1 
through November 30, 2005, we conducted a retrospective 
study of 19 eyes of 18 patients who received IVT injection 
for postvitrectomy diabetic vitreous hemorrhage. The 19 eyes 
in this study included those who previously had three-port SY Lee, et al. IVT FOR POSTVITRECTOMY DMVH
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Patient
No.
Age/Sex/
Laterality Post-op Dx
*   Ocular history Interval from PPV to 
IVT (wk)
†
VH scale 
(Grade) Lens status Duration of followup 
(wk)
1 44/M/OS DMVH PPV 14 3 IOL 26
2 47/M/OD DMTRD/VH PPV,SR 14 1 Phakic 36
3 41/F/OS DMTRD/VH PPV 50 1 IOL 34
4 77/F/OS DMVH PPV 68 1 IOL 37
5 77/F/OD DMVH PPV 83 3 IOL 37
6 63/M/OD DMVH PPV 42 1 IOL 35
7 58/F/OS DMTRD/VH PPV 17 3 IOL 26
8 67/F/OS DMTRD/VH PPV 14 3 IOL 30
9 57/F/OS DMTRD/VH PPV 4 2 Phakic 32
10 68/F/OS DMVH PPV 9 3 IOL 29
11 66/F/OD DMTRD/VH PPV 1 1 IOL 26
12 50/M/OS DMVH PPV 7 3 IOL 17
13 38/M/OS DMTRD/VH PPV 42 1 IOL 20
14 45/M/OS DMVH PPV 14 3 IOL 32
15 48/M/OD DMTRD/VH PPV 14 1 IOL 36
16 59/F/OD DMVH PPV 7 3 IOL 14
17 63/M/OS DMVH PPV 14 2 IOL 14
18 52/F/OD DMVH PPV 4 3 IOL 26
19 51/F/OS DMVH PPV 11 2 IOL 28
* postoperative diagnosis of prior vitrectomy 
†Interval between last procedure (pars plana vitrectomy, silicone oil removal) and 
intravitreal triamcinolone acetonide injection (weeks).
DMTRD, diabetic tractional retinal detachment; DMVH, diabetic vitreous hemorrhage; PPV, pars plana vitrectomy; IVT, intravitreal 
triamcinolone acetonide injection; SR, silicone oil removal; IOL, intraocular lens.
Table 2. Patient and Recurrent Vitreous Hemorrhage Characteristics
D e s c r i p t i o n                                        G r a d e
N o  v i t r e o u s  h e m o r r h a g e                                                              0
Mild vitreous hemorrhage with visible fundus details 1
Moderate vitreous hemorrhage with no visible fundus details but with an orange fundus reflex 2
Severe vitreous hemorrhage with no retinal details and no orange fundus reflex 3
Table 1. Intravitreal Hemorrhage Scaling according to the Diabetic Retinopathy Vitrectomy Study
pars plana vitrectomy, with or without cataract operation for 
nonclearing vitreous hemorrhage (11 eyes), and vitreous 
hemorrhage with traction retinal detachment (8 eyes). The 
risks and benefits of the procedure were discussed with each 
patient before injection, and all patients provided written 
informed consent. This study had Institutional Research 
Board approval.
The degree of intravitreal hemorrhage was scaled 
according to the diabetic retinopathy vitrectomy study 
grading system (Table 1).
17  Baseline parameters were 
documented, including visual acuity, intraocular pressure 
(IOP), lenticular status and retinal attachment through the 
B-scan. The eye was cleansed with 10% Betadine (Becetin
Ⓡ, 
Hyundai Pharm, Seoul, Korea) solution. A sterile lid 
speculum was placed in the eye, and sterile topical lidocaine 
was used to anesthetize the inferotemporal quadrant. 
Triamcinolone acetonide (4 mg/0.1 ml; TRIAM
Ⓡ; Shinpoong, 
Seoul, Korea) was injected inferotemporally through the pars 
plana using a 30 gauge needle on a tuberculin syringe.
Response to treatment was monitored on day 1, weeks 1, 
2, and 4, and months 2 and 3 by Snellen visual acuity and 
biomicroscopic examination. IOP was recorded at every visit, 
along with potential corticosteroid-induced and injection- 
related complications. Other assessments included ocular 
history, adverse events, external eye examination, fundus 
examination, B-scan ultrasonography, and fundus photography.
Results
A total of 19 eyes from 18 patients were reviewed. 
Patient's age, gender, ocular laterality, diagnosis of prior 
vitrectomy, and interval between vitrectomy and IVT 
injection are described in Table 2.
The visual acuity of 15 eyes at the time of IVT injection 
ranged from LP to CF, and in 4 eyes the visual acuity was 
slightly better than CF. Nine eyes had grade 3 VH (severe 
vitreous hemorrhage with no retinal details and no orange 
fundus reflex), 2 eyes had grade 2 VH (moderate vitreous Kor J Ophthalmol Vol.21, No.4, 2007
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Patient No.
Change in VH scale Change in VA
Comment
#
Early Best Final Early
‡ Best (week)
§ Final
Π
1 3 0 0 CF 20/100(3) 20/50
2 1 0 0 20/250 20/125(1) CF Recurred VH/AFX, VW
3 1 0 0 CF CF(1) 20/250
4 1 0 0 CF 20/80(1) 20/40
5 3 0 0 HM 20/200(5) 20/100
6 1 0 0 20/200 20/63(2) 20/80
7 3 3 0 HM CF(1) 20/50 Nonclearing VH, AFx
8 3 0 0 CF 20/250(3) 20/250 Recurred VH/VW, SO
9 2 0 1 HM 6/200(1) 20/320 Recurred VH/VW
10 3 0 0 HM CF(1) 20/250
11 1 0 0 CF 20/100(3) 20/200
12 3 0 0 LP 20/125(2) 20/50
13 1 0 0 6/200 20/100(1) 20/40
14 3 0 0 CF 20/100(3) 20/25
15 1 0 0 20/320 20/125(1) 20/200 Recurred VH/AFx, VW
16 3 3 0 CF CF(1) 20/320 Nonclearing VH/AFx
17 1 0 0 HM 6/200(1) 20/320
18 3 0 0 CF 20/63(2) 20/50
19 2 0 0 HM 6/240(1) 20/200 Recurred VH/AFx
‡VA at the time of IVT injection 
§VA at the time of clearing of VH (post IVT injection week) 
ΠVA at last follow-up 
#Patient Nos. 
2, 8, 9, 15 and 19 developed recurrent VH after clearing of VH and these patients underwent air-fluid exchange or vitreous cavity
washout.
VH, vitreous hemorrhage; AFx, air-fluid exchange; VW, vitreous cavity washout; SO, silicone oil tamponade.
Table 3. Summary of Changes in VH Scale and Visual Acuity
Fig. 1. Fundus photograph of patient No. 17 showing the 
inferior peripheral aspect of retina at 1 week after intravitreal 
triamcinolone injection for recurrent postvitrectomy diabetic 
hemorrhage. Previous laser photocoagulation scars (upward) 
and whitish precipitation of triamcinolone with reddish blood 
clots on the precipitation (downward, arrow) can be seen.
hemorrhage with no visible fundus details but with orange 
fundus reflex) and 8 eyes had grade 1 VH (mild vitreous 
hemorrhage with visible fundus details). Mean follow-up 
after IVT injection was 28 weeks (range, 14-37 weeks). The 
vitreous hemorrhage was cleared in 17 of the 19 eyes (89%) 
within 1 to 5 weeks (mean, 1.7 weeks); in 11 of these 17 
eyes, it was cleared within 1 week (Table 3). The fundus was 
clearly visible in all 17 of VH clearing eyes, and 
triamcinolone precipitates were observed along with retained 
blood clots (Fig. 1). All but one of these 17 eyes had visual 
improvement, with a mean visual acuity of 20/160 (range, CF 
to 20/63) within 1 to 5 weeks. At last follow-up, 12 of the 
17 eyes maintained VH-free condition with the mean visual 
acuity of 20/63. (range, 20/320 to 20/25) Of the 17 eyes that 
cleared, 5 subsequently developed recurrent vitreous 
hemorrhage, and these underwent air-fluid exchange or 
vitreous cavity washout. VH was not cleared in 2 eyes, and 
vitreous cavity washouts were performed.
IOP increased in 7 eyes during the follow-up period; in 
one, increased IOP was due to recurrent VH. Of the 7 eyes, 
6 were treated with topical antiglaucomatous medication and 
1 was managed for recurrent VH. There was no significant 
cataract progression in the 2 phakic eyes, and no 
procedure-related complications during follow-up.
Discussion
VH is the most common complication of vitrectomy for 
diabetic retinopathy. Despite measures to prevent and control 
this bleeding, it can lead to air-fluid exchange in the office 
or to additional surgery in the operating room. Air-fluid 
exchange does not result in clear vision immediately after the 
procedure, and the patient has to maintain a face-down 
position. Vitreous lavage combined with/without air 
tamponade, a more invasive procedure performed in the 
operating room, may give rise to complications such as 
iatrogenic retinal breaks, incarcerations of vitreous in the 
sclerotomy sites, retinal detachment, rubeosis iridis, 
neovascular glaucoma and infective endophthalmitis.
18 With SY Lee, et al. IVT FOR POSTVITRECTOMY DMVH
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lack of large number of patients, longer follow-up and control 
group, it is hard to say that IVT injection is superior to 
common standard treatment such as air-fluid exchange and 
vitreous lavage or as much efficient as those treatments. 
However, in our study, most eyes with clearing VH improved 
their visual acuity within 1 to 5 weeks (mean; 1.7 weeks) and 
in 11 of these 17 eyes, VH was cleared within 1 week. Thus 
possibly more rapid clearing of VH by IVT injection than 
natural course may enable faster visual rehabilitation and 
additional laser photocoagulation which may prevent 
recurrence of VH. When spontaneous clearing occurred, it 
usually did so in 7-11 weeks.
6 Additionally, in terms of less 
invasiveness and avoiding face-down position, IVT injection 
may be more convenient.
It is still unclear how IVT injection can cause clearing the 
vitreous hemorrhage. We suppose that the mechanical 
downward sedimentation of triamcinolone in the vitreous 
cavity with the adherent remaining blood may play a role 
since this phenomenon is always observed once the fundus 
becomes visible.. One thing remarkable is that IVT injection 
is only useful for VH in the vitrectomized eye rather than 
non-vitrectomized eye to our best knowledge. Considering 
the difference in vitrectomized and non-vitrectomized eye, we 
are presuming a 'sedimentation' theory. In addition, induction 
of direct vascular stabilizing effect may play a role in 
maintaining VH-free condition. At the time of last follow-up 
(mean, 28 weeks), 12 of 19 eyes maintained their VH-free 
condition.
With respect to the VH scale, the 2 eyes that did not clear 
were grade 3. Of the 17 eyes that cleared, 8 eyes were grade 
1, 2 eyes were grade 2, and 7 eyes were grade 3. The 5 eyes 
that showed recurrent hemorrhage varied in VH scale from 
grades 1 to 3. With this small sample size, we can not find 
any statistical significant relationship between VH scale and 
efficacy of IVT injection.
Significant adverse effects of the IVT injection procedure 
were infrequent. The remarkable complications were 
non-clearing of the vitreous hemorrhage, requiring vitreous 
cavity washout in 2 eyes (10%), recurrent vitreous 
hemorrhage in 5 eyes (26%), and procedure related IOP 
increase in 6 eyes (31%) which were controlled well with 
topical antiglaucomatous agent. There was no evidence of 
cataract progression in the 2 phakic eyes.
IVT injection can delay surgical intervention. With early 
treatment of preproliferative diabetic retinopathy and 
advancement of vitrectomy, the risk of anterior hyaloidal 
fibrovascular proliferation can be decreased. Additionally, 
triamcinolone has anti-proliferative and anti-inflammatory 
properties. IVT injection combined with pars plana vitrectomy 
as an adjunct treatment of proliferative vitreoretinopathy was 
shown to lower intraocular inflammation, postoperative pain 
and incidence of re-operations caused by preretinal fibrous 
membrane formation.
10,19 Triamcinolone may induce 
regression of neovascular iris vessels.
20-21 Thus, delaying 
surgical intervention through IVT injection does not appear 
to negatively affect final visual outcome. In this study, 
fibrovascular ingrowths at sclerotomy sites were not found in 
nonclearing VH or recurrent VH that required vitrectomy. 
We recognize that the limitations of our work include a 
small sample size; no comparison with natural course of 
recurrent VH; limited success in clearing VH, and relatively 
short follow-up time. Despite these limitations, IVT injection 
as an optional treatment of post vitrectomy diabetic VH is 
a less invasive procedure that possibly provides quicker 
visual recovery while avoiding the patient keeping a 
face-down position.
In conclusion, IVT injection may be beneficial for prompt 
clearing of recurrent postvitrectomy diabetic VH and 
maintaining VH-free condition, possibly by mechanical 
sedimentation with retained blood clots and the vascular 
stabilizing effects of triamcinolone. We have started on a 
randomized controlled clinical trial with air-fluid exchange 
and IVT injection to assess the safety and efficacy with long 
term follow up. 
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